drugset / Trial / NCT05628545
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
NaSingle-groupOpen-labelTreatment
Summary
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients. The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2023-02-28
- Completion
- 2024-10-31
Outcome
Outcome not reported
Stopped: “COVID1-19 pandemic”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GDKM-100 | Cell therapy | 2e+08 cells | — |
| Subject | GDKM-100 | Cell therapy | 5e+08 cells | — |
| Subject | GDKM-100 | Cell therapy | 1e+09 cells | — |